Juntendo Medical Journal
Online ISSN : 2188-2126
Print ISSN : 2187-9737
ISSN-L : 2187-9737
Health Topics for Tokyoites: Latest Rheumatoid Arthritis Medical Care and Its Important Points
New Therapy in Rheumatoid Arthritis ˜ Biological DMARDs and JAK Inhibitors ˜
KURISU TADA KEN YAMAJINAOTO TAMURA
Author information
JOURNAL OPEN ACCESS

2020 Volume 66 Issue 1 Pages 34-37

Details
Abstract

With the advent of biological disease modifying anti-rheumatic drugs (DMARDs) and Janus kinase (JAK) inhibitors as a new treatment for rheumatoid arthritis (RA), the treatment of RA has made a dramatic progress. The new treatment not only suppresses the joint swelling and tenderness but also it can maintain the function of daily life, further suppress joint destruction and aim for remission. Biological DMARDs and JAK inhibitor have the advantage that their effect is prompt and high efficacy is sustained over a long period of time, while disadvantages such as high risk of infection and high cost of treatment. Especially infection is serious side effect, but patients themselves should seek medical institutions promptly without missing a change in their physical condition, regularly conduct inspections even when there is no symptoms prevent infectious diseases in advance. It is important to have correct knowledge and share direction of treatment with their doctor.

Content from these authors
© 2018 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.

This article is licensed under a Creative Commons [Attribution 4.0 International] license.
https://creativecommons.org/licenses/by/4.0/
Previous article Next article
feedback
Top